KU812 Xenograft Model Service for CML

The KU812 cell line serves as a versatile and clinically representative in vivo platform for investigating Chronic myeloid leukemia (CML), particularly for evaluating therapeutic responses in patients presenting with basophilic differentiation. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision KU812 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your CML drug discovery and development pipeline.

Overview of KU812 Xenograft Model for CML

The KU812 xenograft model is an established in vivo translational system widely utilized in hematological oncology research for the study of CML. By transplanting human KU812 myeloid cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles characteristic of progressive human CML.

Biologically, the KU812 model is highly valued for its consistent engraftment profiles and predictable disease progression, which provide investigators with a reliable experimental window for evaluating complex dosing schedules and pharmacodynamics. This model preserves critical human myeloid molecular features, including the expression of BCR-ABL1 and unique basophilic characteristics, which are essential for evaluating novel therapeutic strategies. Consequently, the KU812 model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Fig 1. h4#147D vs gemcitabine, imatinib, sorafenib in KU812 CML xenograft NOD SCID mice. (Fukuchi K, et al., 2022)

Cell Line Information: KU812

The KU812 cell line is derived from the peripheral blood of a patient diagnosed with CML in the blast crisis phase. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable phenotype with basophilic differentiation potential that serves as a robust proxy for hematological cancer research.

Our Services

Workflow of KU812 Xenograft Model Construction

• Cell Culture & Quality Control: Human KU812 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability KU812 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. KU812 Xenograft Model Construction Workflow

Case Study - KU812 Xenograft Model Development

A pre-clinical validation study was conducted using the KU812 xenograft model to evaluate the therapeutic efficacy of a novel targeted inhibitor designed for CML. Following precision intravenous inoculation of human KU812 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted CML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and myeloid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your CML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our KU812 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.